3D Medicines (HKG:1244) has filed for patent under the Patent Cooperation Treaty for a key component of its ionizable cationic lipid in the lipid nanoparticles for nucleic acid drug delivery, a Tuesday filing with the Hong Kong bourse said.
The biopharmaceutical company has created an ionizable cationic lipid R&D platform targeting different cell types and organs by using AI to design and screen hundreds of lipid compounds.
The platform synergizes with the development of the firm's self-developed mRNA cancer vaccine projects, the company said.